Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors

Blood

Volumn 113, Issue 23, 2009, Pages 5727-5736

  Lim, Ken Hong ^a,b   Tefferi, Ayalew ^a   Lasho, Terra L ^a   Finke, Christy ^a   Patnaik, Mrinal ^a   Butterfield, Joseph H ^a   McClure, Rebecca F ^a   Li, Chin Yang ^a   Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGE; AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ALLELE; ANEMIA; ARTICLE; BLAST CELL; BONE MARROW; CELL LINEAGE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; INDOLENT SYSTEMIC MASTOCYTOSIS; LEUKEMOGENESIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MAST CELL; MAST CELL LEUKEMIA; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS ASSOCIATED CLONAL HEMATOLOGIC NON MAST CELL LINEAGE DISEASE; THROMBOCYTOPENIA; TREATMENT PLANNING; WEIGHT REDUCTION; AGED; BLOOD; BONE MARROW DISEASE; CELL TRANSFORMATION; CLASSIFICATION; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW DISEASES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 67651120132     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205237     Document Type: Article

References (32)

1. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91:612-624.
2. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345-368. (Pubitemid 19003322)
3. Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc. 1986;61:957-966. (Pubitemid 17205206)
4. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965-972. (Pubitemid 18231498)
5. Czarnetzki BM, Kolde G, Schoemann A, Urbanitz S, Urbanitz D. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol. 1988;18:45-51. (Pubitemid 18047864)
6. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999;94:2333-2342. (Pubitemid 29467681)
7. Brunning RD, McKenna RW, Rosai J, Parkin JL, Risdall R. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol. 1983;7:425-438.
8. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol. 1985;16:808-814. (Pubitemid 15040816)
9. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731-2736. (Pubitemid 28227522)
10. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004;28:777-783. (Pubitemid 38760039)
11. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372. (Pubitemid 44497521)
12. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560-10564.
13. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-625. (Pubitemid 32506768)
14. Valent P, Horny H-P, Li C-Y, et al. Mastocytosis (Mast Cell Disease). In: Jaffe E, Harris N, Stein H, Vardiman J, eds. WHO Classification of Tumours Pathology and Genetics Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:292-302.
15. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279-2284. (Pubitemid 46801558)
16. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933-942.
17. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed. 1985;19:197-207. (Pubitemid 15098487)
18. Therneau TM, Offord J. Technical Report Series No. 63, Expected Survival Based on Hazard Rates (Update). Department of Health Sciences Research, Mayo Clinic: Rochester, MN; 1999.
19. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677-690. (Pubitemid 36104422)
20. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol. 2006;19:595-615. (Pubitemid 43869476)
21. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007;131:784-791. (Pubitemid 46726143)
22. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635-641. (Pubitemid 36398099)
23. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Feb 2. [Epub ahead of print].
24. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222-3225. (Pubitemid 38451702)
25. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045. (Pubitemid 39507117)
26. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
27. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096. (Pubitemid 37314742)
28. Verstovsek S, Kantarjian H, Cortes J, et al. Dasatinib (Sprycel) therapy for patients with systemic mastocytosis. Blood (ASH Annual Meeting Abstracts). 2006;108: Abstract 3627.
29. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008;80:456-458.
30. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008;38:869-873.
31. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009;33:735-741.
32. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529-536. (Pubitemid 32506759)